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The completion of the Mammalian Gene Collection
(MGC)
The MGC Project Team1
Since its start, the Mammalian Gene Collection (MGC) has sought to provide at least one full-protein-coding sequence
cDNA clone for every human and mouse gene with a RefSeq transcript, and at least 6200 rat genes. The MGC cloning
effort initially relied on random expressed sequence tag screening of cDNA libraries. Here, we summarize our recent
progress using directed RT-PCR cloning and DNA synthesis. The MGC now contains clones with the entire protein-coding
sequence for 92% of human and 89% of mouse genes with curated RefSeq (NM-accession) transcripts, and for 97% of
human and 96% of mouse genes with curated RefSeq transcripts that have one or more PubMed publications, in addition
to clones for more than 6300 rat genes. These high-quality MGC clones and their sequences are accessible without
restriction to researchers worldwide.
[Supplemental material is available online at http://www.genome.org. The accession nos. and properties of all clones and
sequences are listed in the Supplemental material and at ftp://ftp.ncbi.nih.gov/repository/MGC/MGC_project/.]
cDNA clones containing the entire protein-coding sequence of
mRNA transcripts (full-CDS clones), together with corresponding
high-quality sequences, are essential resources for annotating
protein-coding genes on genomes and for expressing the protein
products of those genes. The Mammalian Gene Collection (MGC)
was established as a multi-institute effort at the National Institutes
of Health (NIH) to provide the research community with unrestricted access to sequence-validated human and mouse full-CDS
clones and their sequences (Strausberg et al. 1999).
The goal for MGC at the outset, in 2000, was to provide at
least one sequence-validated, full-CDS clone for each known human and mouse gene. A similar cDNA cloning program was funded
later for 6200 rat genes. The MGC high-throughput cloning, sequencing, and distribution infrastructure was also used for fullCDS cloning programs for Danio rerio (ZGC; http://zgc.nci.nih.
gov/) and Xenopus laevis and Xenopus tropicalis (XGC; http://xgc.
nci.nih.gov/).
MGC clones initially were obtained by randomly picking
5000–20,000 colonies from custom cDNA libraries and end-sequencing the plasmid inserts. Those representing genes absent
from the collection were fully sequenced (Strausberg et al. 2002).
Using this approach, by June 2004 the MGC had acquired full-CDS
clones for 11,727 unique human genes, 10,171 unique mouse
genes, and 828 unique rat genes (Fig. 1), isolated from 154 human,
131 mouse, and 33 rat libraries, derived from a wide variety of
tissues and cell lines (Gerhard et al. 2004). Putative full-CDS clones
were sequenced to high quality, that is, with no uncertain base
calls and an average error rate of <1 error in 50,000 bp. Descriptions
of these libraries and their tissue sources are available at http://
mgc.nci.nih.gov/.
The progress of the MGC, XGC, and ZGC cloning programs,
from their start to March 2009, is shown in Figure 1, which also
gives the total numbers of genes represented and the total numbers
of clones in each collection. This report focuses on the MGC efforts
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to complete the human, mouse, and rat collections since the last
MGC publication, in 2004 (Gerhard et al. 2004).
As the number of human and mouse full-CDS clones approached approximately 10,000, random EST screening of cDNA
libraries yielded cDNA clones for progressively fewer unique genes
over time (Fig. 2), and for fewer genes per thousand ESTs analyzed
(data not shown), significantly raising the cost of obtaining clones
for the unrepresented genes. Pilot studies to improve yield with
normalized cDNA libraries and protocols that favored cDNAs for
rarer transcripts and longer inserts also introduced additional
mutations, yielding an increased rate of nucleotide variation in the
cDNAs compared to the genome (Gerhard et al. 2004). Therefore, two
alternative approaches—directed RT-PCR cloning (‘‘PCR rescue’’) and
DNA synthesis—were implemented to obtain clones for the missing
genes. These approaches and their results are described below.

Results
PCR rescue
We selected targets for PCR rescue from RefSeq transcripts (Pruitt
et al. 2009b) for human and mouse genes not represented by fullCDS clones in MGC (see Methods). In cases of multiple transcript
isoforms, we chose the isoform with the longest CDS supported by
transcript and protein homology in other mammalian species.
These targets were divided into two sets, with each assigned to one
of two laboratories. The methods used by each laboratory have
been described (Baross et al. 2004; Wu et al. 2004). Targets that
failed to be isolated at one laboratory were exchanged with the
other for a second attempt. A full list of the RefSeq transcripts and
their corresponding genes assigned for PCR rescue (together with
the CDS sizes and the outcome of each transcript’s PCR rescue) is
given in Supplemental Table A.
PCR rescue recovered 8862 full-CDS clones for 4088 human
genes (Fig. 2A) and 4774 mouse genes (Fig. 2B). RT-PCR reactions
frequently displayed additional bands on gel electrophoresis,
which cloning and sequence analysis often revealed as alternative
splice isoforms of the targeted transcript (M Hirst, T Zeng, K Tse, A
Delaney, J Pang, J Wang, G Taylor, A Deng, M Moksa, K Fichter,
et al., in prep.). Clones of isoforms with a CDS length at least 50% of
the CDS length of the targeted transcript were accepted by MGC, as
long as they met criteria consistent with a full CDS (see Methods).

19:2324–2333 Ó 2009 by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/09; www.genome.org

Downloaded from genome.cshlp.org on December 18, 2013 - Published by Cold Spring Harbor Laboratory Press

Completion of the Mammalian Gene Collection (MGC)

Figure 1. Cumulated gene counts for MGC, XGC, and ZGC. The progressive addition of clones, measured by genes represented in each collection, is
shown for MGC, XGC, and ZGC from the beginning to conclusion of these programs. ‘‘Gene Count’’ is the total final number of RefSeq genes represented
by each set of clones. This number includes some noncurated genes (XM accessions) that are not counted in Table 1. ‘‘Clone Count’’ includes all clones,
including duplicate transcripts and isoforms. Isoforms constitute 2%–3% of the human, mouse, and rat collections.

Target size most strongly influenced the outcome, with 64%–
70% success for 0.1–3-kb targets falling progressively to zero for
targets of 9 kb and larger (Fig. 3). Success also correlated inversely
with the level of mRNA expression (Supplemental Fig. S1). Overall,
one or more full-CDS clones were obtained for 65% of targeted
genes.

DNA synthesis of full-CDS clones
After two attempts at PCR rescue, MGC still lacked full-CDS clones
for about 2200 human genes and about 1800 mouse genes with
curated RefSeq transcripts (accession prefix NM_). Compared to
the expense for further attempts at PCR rescue, DNA synthesis
provided a cost-effective alternative for obtaining clones for transcripts of most outstanding genes in MGC.
DNA synthesis also made it practical to synthesize the CDS
precisely, without additional 59- or 39-untranslated region (UTR)
sequences, facilitating the subsequent use of these clones to produce proteins with N-terminal and C-terminal fusion tags using
the Gateway cloning system. The MGC full-CDS clones generated
by DNA synthesis were prepared in a Gateway Entry vector, permitting the subsequent transfer of inserts into a wide range of
expression vectors by site-specific recombination (Hartley et al.
2000), a transfer method with a very low risk of introducing mutations into the transferred inserts (JL Hartley, unpubl.).
The protein-coding sequences of 3647 RefSeq accessions
supported by known transcripts and protein orthologs were
assigned for DNA synthesis to two companies (Methods). The
numbers and sizes of human and mouse transcripts assigned for
synthesis and the rate of success for each size category are given in
Figure 4. The contributions of DNA synthesis to the total MGC
human and mouse full-CDS clone collections are displayed in
Figure 2, A and B. DNA synthesis provided MGC with full-CDS
clones for 86% of the 3414 outstanding genes assigned. Synthesis
succeeded for 94% of targets with a CDS of 4 kb or less, but success fell
dramatically for larger targets (11% of 46 targets with CDS >10 kb).
Finally, 318 cDNA clones for 126 high-priority genes that had
failed one or more attempts at synthesis and stable cloning of
a full-CDS were accepted by MGC with the CDS cloned in two or

more fragments. For 92 of these genes, the partial-CDS clones together compose the entire CDS (Supplemental Table B).

Predictions of new human genes
Multi-exon gene predictions
Starting in 2005, MGC sought to predict human multi-exon genes
absent from the RefSeq and other major gene catalogs. We used
algorithms that relied primarily on comparative sequence data,
with or without existing EST or cDNA evidence: N-SCAN (Gross
and Brent 2006), N-SCAN_EST (Wei and Brent 2006), Exoniphy
(Siepel and Haussler 2004), and TransMap (Zhu et al. 2007). Results
were confirmed by sequencing RT-PCR products of two or more
spliced exons in the predicted transcripts from each postulated
gene locus. This effort identified 734 novel gene fragments (NGFs)
containing 2188 exons with little or no prior cDNA support, corresponding to an estimated 563 distinct genes. At the time of this
analysis, 327 of these genes were completely absent from the
cDNA-based RefSeq and Vega gene catalogs (Wilming et al. 2008;
Pruitt et al. 2009b), and 178 were also absent from the Ensembl
collection (Hubbard et al. 2009). Many other gene fragments were
identified that represented extensions of known genes. These
novel fragments contributed transcript evidence for 480 RefSeq
accessions later assigned for PCR rescue. For seven of these accessions, the NGFs provided the only direct transcript support. Details
of the methods and results of this program were published in 2007
(Siepel et al. 2007). Subsequent to our analysis, 42 genes overlapping the novel gene fragments have been added to RefSeq.

Single-exon gene predictions
To minimize the inclusion of pseudogene transcripts and other
non-protein-coding sequences in the MGC, our random-EST
cloning and PCR rescue efforts intentionally excluded transcripts
of single-exon genes (SEGs) and transcripts potentially encoding
proteins of fewer than 100 amino acids (Strausberg et al. 2002).
These criteria excluded the isolation of transcripts of authentic
single-exon genes and some multi-exon genes encoding short
protein-coding transcripts, such as for some human olfactory
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Figure 2. MGC progress represented over time by method. (A) Human; (B) mouse. The absolute contribution (by genes represented) of each cloning
method is shown for EST-based cloning, PCR-Rescue, and DNA synthesis, over time.

receptors (Carninci et al. 2005; Glusman et al. 2006; The ENCODE
Project Consortium 2007).
To assess how many SEGs are not annotated in current gene
catalogs, we considered all open reading frames (ORFs) longer
than 200 bp in the human genome. We used logistic regression
analysis to select 351 ORFs most likely to encode unannotated
SEGs, based on features such as cross-species conservation, protein
homology, and genome-wide expression data (Methods). These
candidate SEGs were tested for expression by RT-PCR, with no-RT
controls to detect results due to genomic contamination. Expression was confirmed in 198 out of 351 candidates (57%) (Supplemental Table S1). Additional RT-PCR experiments, using RNA from
several tissues and variable numbers of PCR cycles, suggested that
these SEG candidates are expressed at low levels and in a tissuespecific manner, especially in the testes and cerebellum. However,
a large fraction of negative reference loci (selected from annotated
pseudogenes and regions annotated as intronic or intergenic by
the ENCODE pilot project) also showed evidence of expression by
RT-PCR, consistent with previous reports (Carninci et al. 2005;
Glusman et al. 2006; The ENCODE Project Consortium 2007).
Attempts to confirm expression at the protein level were in-
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conclusive, with only nine of 198 positive candidates and six of the
138 negative reference loci matching peptide mass spectrometry
(MS) spectra (http://bioinfo2.ucsd.edu/MSGeneAnnotation/index.
html), perhaps in part owing to low levels of protein expression
and incomplete databases of peptide MS spectra. Thus, whether
these 198 candidate SEGs are true protein-coding genes remains
an open question.
These ambiguous results underscore the challenge of obtaining
a fully comprehensive set of human protein-coding genes, given
pervasive genomic transcription, expressed pseudogenes, and true
genes that are expressed transiently and at low levels. Although our
genome-wide search for candidate SEGs turned up relatively few
instances with, at best, questionable evidence for protein-coding
function, our methods could have overlooked some fast-evolving,
very short, lineage-specific, or recently duplicated genes.

Final numbers of genes represented by MGC clones
Table 1 gives the final numbers of human, mouse, and rat genes
represented by one or more full-CDS clones in the MGC, compared
to the totals for four classes of protein-coding genes. The MGC now
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Figure 3. PCR rescue success versus target size. (Black bars) The number of assigned targets in each size range; (white bars) the number of
assigned targets that were obtained as full-CDS clones, with the number
of clones recovered shown above the bars. The triangles and trendline
show the percentage recovered for each size group. Excluded from these
calculations are RefSeq targets where the assigned CDS later was changed,
suppressed, or withdrawn over the course of the PCR rescue program.
Among 8764 human and mouse targets with changed annotation, we
obtained a full-CDS clone for 3197 (36%), including one 10.8-kb clone
(BC150731).

contains clones for 92% of human genes, 89% of mouse genes, and
41% of rat genes with RefSeq curated (NM accession) transcripts,
regardless of publication status (line A); and contains full-CDS
clones for 97% of human genes, 96% of mouse genes, and 44% of
rat genes with one or more PubMed publication (line B). Table 1
also shows that MGC includes full-CDS clones for 93% of human
genes linked to a disease phenotype (line C), and for 95% of human and 93% of mouse transcripts listed as highly curated Consensus CDS (CCDS) transcripts (line D) (Pruitt et al. 2009a). The
RefSeq transcripts for the genes represented in Table 1 and the
corresponding accessions of MGC clones are given in Supplemental Table C; and genes lacking full-CDS clones in MGC are
listed in Supplemental Table D. The size distributions of the final
MGC human and mouse clone collections, compared to the longest RefSeq transcript isoforms, are shown in Supplemental Table
S8. The relationships between the MGC, RefSeq, and Ensembl
human and mouse gene sets are shown in Figure 5.

Supplemental Table S2 presents the rates of sequence discrepancy, based on total sequences of human and mouse clones,
together with the percentages of discrepancies that correspond to
validated polymorphisms in dbSNP. Because the mouse reference
genome sequence was derived from a single mouse strain, C57BL/6,
the variation in MGC mouse clones was divided into three categories, based on the strains that provided the RNA: C57BL/6 and
C57BL/6J; other known strains, including crosses to C57BL/6J; and
undocumented strains.
The variation per nucleotide observed in human MGC clone
coding and noncoding human sequences compared to the human
reference genome (Supplemental Table S2) is 9.1 3 10 4, 44.6% of
which is validated polymorphism in dbSNP (defined in the footnote to Table 2). For MGC mouse clones, the variation frequency
and percentage of variation in dbSNP vary with the strain of mouse
RNA used to prepare the clones. As expected, both the variation
(3.8 3 10 4) and the percent variation documented in dbSNP
(4.6%) are lowest for clones derived from C57BL/6.

Sequence variation due to RNA editing
Sequence discrepancies in MGC clones can also reflect post-transcriptional editing of mRNA, which in mammalian cells is due almost exclusively to A-to-I editing, mediated by the adenosine deaminases acting on RNA (ADAR) family of enzymes (Bass 2002;
Gommans et al. 2008). The resulting inosine in the edited RNA is
read as guanosine by the in vivo cellular machinery, as well as by
the enzymes used in cDNA cloning and sequencing. To date, only
about 70 human mRNAs have been reported to contain A-to-I
editing sites in the CDS (Supplemental Table S3), whereas several
thousand examples of A-to-I editing in noncoding sequences of
the 59 and 39 UTRs and within introns of human pre-mRNA sequences have been reported (Athanasiadis et al. 2004; Kim et al.
2004; Levanon et al. 2004; Li et al. 2009).
We sought to identify candidate A-to-I editing sites in MGC
clones. Because MGC has produced only a single full-CDS clone for
most genes, we could not use the occurrence of coincident edits
within multiple clones to identify loci of selective RNA editing.
Therefore, we used two different tests to focus on identifying
clones statistically enriched for clusters of A-to-G changes compared to the genome sequence (Supplemental Text S3). These two
tests detected 118 MGC clones with potential editing sites, of
which 87 were identified by both tests (Supplemental Tables S4, S5,

Sequence variation in MGC clones
MGC clone variation versus dbSNP
The full-CDS sequences for all clones submitted to MGC were
compared to their corresponding reference genome (human clones
were also compared to the chimpanzee reference genome). Discrepancies between a cDNA and its reference genome are annotated in the GenBank records, with links to polymorphisms
recorded in dbSNP.
Table 2 shows the sequence discrepancies (single-nucleotide
mismatches and indels) found between MGC clones and the reference human (version 36.3) and mouse (version 37.1) genomes,
expressed as the number of differences observed per clone. Among
human clones, 57% contain no mismatch in the CDS and 72% no
nonsynonymous (NS) mismatches. Similarly, 66% of mouse clones
contain no mismatches in the CDS and 79% no NS mismatches.
Thus, the majority of clones are free of any differences in the CDS;
and 72% of human and 79% of mouse clones are free of NS changes.

Figure 4. Synthesis success versus target size. (Black bars) The number
of assigned targets in each size range; (white bars) the number of assigned
targets that were obtained as full-CDS clones, with the number of clones
recovered shown above the bars. The triangles and trendline show the
percentage recovered for each size group. RefSeq targets where the
assigned CDS later was changed, suppressed, or withdrawn (233 in total)
were excluded from these calculations.
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Table 1.

MGC achievement
Protein-coding genes

Protein-coding genes in MGC

Gene classesa

Human

Mouse

Rat

Human

Mouse

Rat

A. All genes with curated RefSeq transcriptsb
B. Genes with $1 PubMed articles and
curated RefSeq transcriptsb
C. Genes with known disease phenotypec
D. Genes with CCDS transcriptsd

18,877

19,357

15,389

17,421 (92%)

17,285 (89%)

6363 (41%)

14,614
2306
13,884

12,434
2208
15,263

6236
2075
NA

14,102 (97%)
2152 (93%)
13,131 (95%)

11,902 (96%)
2047 (93%)
14,124 (93%)

2724 (44%)
782 (38%)
NA

a

Genes counted in Classes B, C, and D are subsets of Class A and not mutually exclusive.
Curated RefSeq transcripts (NM-accession transcripts) are a subset of RefSeq transcripts that have been validated based on protein and DNA evidence.
c
Human genes in this category were identified by searching OMIM for records with ‘‘phenotype description, molecular basis known’’ and ‘‘gene with
known sequence and phenotype’’ and then retrieving Gene Links that are not in the phenotype-only category. Mouse and rat genes in this category were
identified using NCBI HomoloGene links for the above-mentioned human genes.
d
Consensus CDS (CCDS) includes a subset of transcripts with agreement on the full CDS by annotation specialists at NCBI, European Bioinformatics
Institute, University of California at Santa Cruz, and the Wellcome Trust-Sanger Institute (Pruitt et al. 2009a); because the numbers are based on RefSeq
mRNAs in the CCDS set that are current as of March 23, 2009, they are less than the total CCDS gene number. (NA) Not applicable; CCDS genes have not
been defined for rat.
b

and S6), with an apparent false-positive rate of 2%. Eighty-nine
percent of the clusters of A-to-G changes lie wholly or partially
within Alu repeat sequences, and 88% are within UTRs, consistent
with previous reports (Athanasiadis et al. 2004; Blow et al. 2004;
Kim et al. 2004; Levanon et al. 2004). Eleven clones within this set
of 87 show evidence of CDS editing, including clones for seven
genes that to our knowledge have not been reported previously to
have edits in the CDS (Supplemental Table S7).

Accessing MGC clones
From the years 2000 to 2007, MGC clones were archived at the
IMAGE Consortium (Lawrence Livermore National Laboratories),
which provided MGC clones to the scientific community through
five commercial distributors: Open Biosystems, Life Technologies
(formerly Invitrogen), and ATCC, in the United States; Gene Services Ltd, in the United Kingdom; and imaGenes, in Germany. In
January 2008, all MGC, XGC, and ZGC clones were relocated to
a permanent new archive, at the HudsonAlpha Institute for Biotechnology (HAIB), in Huntsville, Alabama. The HAIB website
(http://image.hudsonalpha.org/) now lists all MGC clones. Scientists wishing to obtain MGC clones can order them, as before, from
the same five commercial distributors.
Table 3 lists the URLs of websites that provide useful information and search tools for users seeking information on and
access to MGC cDNA clones. Searches for MGC clones can begin at
the MGC website (http://mgc.nci.nih.gov/), at the NCBI portal
(http://www.ncbi.nlm.nih.gov/), or at the UCSC Genome Browser
(http://genome.ucsc.edu/). Also listed are tutorials on how to locate
MGC clones and details related to vectors, libraries, and tissue sources.

Discussion
The MGC now provides the scientific community with unrestricted access to high-quality, full-CDS clones and sequences for
92% of human genes and 89% of mouse genes with curated RefSeq
(NM-accession) transcripts, and for 97% of human and 96% of
mouse genes with curated RefSeq transcripts and at least one
publication. The MGC also includes 6363 rat clones, representing
41% of rat genes encoding curated RefSeq protein-coding transcripts. A complete list of MGC full-CDS clones, including isoforms, is provided in Supplemental Table C.
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MGC clone quality
The high sequencing standards used by MGC means that errors in
MGC clone DNA sequence analysis are well below 1 in 50,000 bp.
The protein-coding sequence in the majority of human and
mouse clones perfectly matches its reference genome. Nonsynonymous (NS) changes are absent in 72% of human and 79%
of mouse clones, and 45.7% of NS changes in human clones are
documented as polymorphisms. For mouse clones, the percentage
of NS changes documented as polymorphism varies depending on
the strain used as the source of RNA. All differences from the reference genome are noted in the GenBank record for each MGC
clone.
Assuming that cloning procedures for the human and mouse
clones introduced mutations at roughly similar frequencies and
that the 6.5% of C57BL/6 variation matching dbSNP (Supplemental Table S2) largely represents variation within different
colonies of C57BL/6, the remaining 93.5% of the rate of sequence discrepancy in the CDS (2.7 3 10 4) suggests an upper
limit of 2.5 3 10 4 for the combined frequency of CDS mutations arising from the preparation of the clones, sequencing errors (#0.2 3 10 4), and RNA editing in both mouse and human
clones.
We identified a small percentage of MGC clones with changes
suggesting A-to-I editing of pre-mRNA. As reported previously by
others, most of these putative edited sites lie within UTR sequences and overlap Alu repeat sequences. We also identified new
evidence of A-to-I editing in the CDS of MGC clones for seven
human genes, detected by both of the tests we used (Supplemental
Table S7).
Maintaining high clone quality also depends on researchers
receiving the correct clone for the accessions they have ordered. To
detect and correct well-to-well contamination and errors in the
clone rearraying process, all clones on master plates at LLNL and
HAIB are end-sequenced to confirm their identity, prior to sending
replica plates to MGC commercial distributors. Incorrect clones are
replaced, if a suitable replacement is available, or removed. Results
of this QC process are posted at http://image.hudsonalpha.org/qc/
html/QCoverall.shtml.

Revised genome annotation
While the MGC PCR rescue program was under way, concurrent
progress in human and mouse genome annotations forced MGC
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Figure 5. Venn diagram comparing the number of loci containing
protein-coding genes from MGC, RefSeq, and Ensembl. (A) Human; (B)
mouse. The loci were computed by clustering transcripts from all three
gene sets based on the overlap of the genomic location of the CDS portion
of the exons. When a transcript is not uniquely mapped to the genome,
the clusters for all mappings of that transcript were combined and
counted as one locus. For human, this resulted in 17,239 loci containing
MGC clones, 18,494 loci with RefSeq mRNAs (Pruitt et al. 2009b), and
20,856 Ensembl gene loci (Hubbard et al. 2002). Mouse had 17,455 loci
with MGC clones, 19,064 loci with RefSeq mRNAs, and 23,087 Ensembl
gene loci. Genes counted as shared between any two gene sets exclude
genes in the third set. BLAT (Kent 2002) alignments of MGC clones and
RefSeq mRNAs (NM accessions) obtained from the UCSC Genome
Browser database (Karolchik et al. 2008) for human genome assembly
36.1 and mouse assembly 37, and Ensembl Release 52 were used in the
analysis. Genomic loci serve as an estimate of the number of genes in these
data sets. The counts vary from those seen in Table 1, owing to the different method of computation.

to retire and reassign ;45% of the target sequences assigned
between 2004 and 2007. Updated CDS annotation can, for example, reposition the annotated ATG start codon of a CDS further 59, extending the CDS, or excise a length of CDS sequence
deemed to be a retained intron, or retire a transcript from a likely
pseudogene.
With the conclusion of the MGC project, the GenBank records of MGC clone sequences have been frozen, with no further
updates. What constitutes a full-length coding region for some of
the genes and transcripts for which MGC has clones is likely to
change in the future; therefore, users planning to order MGC
clones will need to monitor for these changes. Users can employ
genome browsers and gene-specific databases, such as NCBI’s
Evidence Viewer, Entrez Gene, and the UCSC Genome Browser,
to view relevant regions of the genome (browsers) or gene-related
information (Entrez Gene). MGC has added a guide (see Table 3) to
its website to help users evaluate MGC clone sequences in light of
current genome annotation.

Future collections
Since its inception, the MGC approaches to cloning cDNAs for
additional genes evolved by exploiting concurrent technical ad-

vances: dramatically cheaper DNA sequencing; improved bioinformatics methods for gene prediction and gene annotation; and
cheaper, more accurate DNA synthesis for building cDNA clones.
These advances made it feasible for MGC to achieve full-CDS clones
for nearly 90% or more of a well-defined set of RefSeq transcript
targets, transcribed from <2% of the human and mouse genomes
(Lander et al. 2001; Venter et al. 2001; Waterston et al. 2002; Carninci
et al. 2005).
Recently our view of the eukaryotic transcriptome has expanded dramatically in size and complexity to include multiple
splice isoforms for 90% or more of multi-exon genes (Kuhn et al.
2009), and a vast network of sense and antisense non-proteincoding RNAs, some of which are well studied (Carthew and
Sontheimer 2009), with many others still largely uncharacterized
and of uncertain biological relevance (Kapranov et al. 2007;
Pheasant and Mattick 2007; Guttman et al. 2009).
These major developments have implications for how one
would build another collection of clones for RNAs of contemporary interest, such as for splice isoforms or non-protein-coding
RNAs. Given the speed and cost efficiency of DNA synthesis, when
the need arises for a particular transcript, a laboratory now can
order most cDNAs to be synthesized. Indeed, this approach may
suffice for many laboratories, given the MGC experience that only
a handful of laboratories ordered entire collections of human or
mouse cDNA clones for large-scale studies, while the overwhelming
majority of customers ordered clones for <10% of the collection
(C Pennacchio, unpubl.).
Yet high-throughput programs to study protein–protein interactions, protein structure, and protein function clearly profit
from access to centralized collections of large numbers of clones.
Such collections offer the scientific community benefits of scale,
by providing clones of lower cost and more uniform quality; by
reducing the waste of duplicated clone preparation within the
community; and by relieving individual laboratories of the burden
of clone quality control and distribution.
Less formal centralized approaches also can provide some of
the same benefits. For example, the ORFeome Collaboration (OC;
http://www.orfeomecollaboration.org/) is an informal network of
laboratories, consisting of 10 contributing academic, commercial,
and government groups (including the MGC), that are cooperating—
largely without dedicated funding—to build a public collection of
human cDNA clones in an expression-convenient format.
The growing emphasis on defining cellular networks, with
myriad interactions of RNA, DNA, and protein, may result in
an increased demand for such centralized collections in the
future.

Methods
Target selection
From all protein-coding genes with RefSeq transcripts annotated
on the human and mouse genomes (Pruitt et al. 2009b), we selected
targets for genes outstanding from MGC based on two properties:
their potential research and medical importance, and the level of
supporting evidence that the transcript represents a CDS-complete
product, as previously described (Strausberg et al. 2002).
For assigning PCR rescue targets, transcripts for human and
mouse genes were ranked by the number of peer-reviewed publications associated with the genes. For genes lacking publications,
orthologs and the number of gene-specific NCBI web queries were
used for ranking. In the initial PCR rescue efforts, some potential
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Table 2. Sequence variation in MGC clones versus RefSeq genomes of human and mouse
No. of
discrepancies
per clone

Clones with no No. of Average no. of
discrepancies Frequency Percent in
clones
discrepancies
per clone
(per kb) dbSNPc
examined
(Fx total)

Humana
Discrepancies in CDS + UTR
9713 (0.36)
Discrepancies in CDS
15,551 (0.57)
NS Discrepancies in CDS
19,636 (0.72)

27,188
27,188
27,188

Mouseb
Discrepancies in CDS + UTR 12,062 (0.47)
Discrepancies in CDS
16,839 (0.66)
NS Discrepancies in CDS
20,205 (0.79)

25,679
25,679
25,679

1.87
0.89
0.47

0.91
0.64
0.33

44.6%
54.6%
45.7%

for any nonsynonymous changes. Targets for
outstanding genes were ranked for research
and medical importance using the same criteria as used for PCR rescue, with additional
weight given to disease genes listed in
OMIM.

PCR rescue

Transcript targets for directed RT-PCR cloning were assigned to two research groups,
at the Baylor College of Medicine and the
British Columbia Cancer Agency Genome
Sequence discrepancies are accepted in MGC clones only if they do not change the phase of reading
Sciences Center. The longest isoform generframe, alter the start or stop codons, or result in a CDS that is <50% of the length of the CDS of the
ally was assigned for PCR rescue. Full delongest isoform.
a
scriptions of the PCR rescue protocols used
89.2% of human discrepancies are single-nucleotide mismatches, and 10.8% are indels, of which
by each center have been published (Baross
11% are in the CDS (1.2% total discrepancies).
b
89.3% of mouse discrepancies are single-nucleotide mismatches, and 10.7% are indels, of which
et al. 2004; Wu et al. 2004). Both groups
8.8% are in the CDS (0.94% total discrepancies).
designed PCR primers flanking the target
c
Percent in dbSNP is based on dbSNP build 129 and represents validated SNPs identified as (1) SNPs
CDS, including varying amounts of UTR sewith allele frequency data; (2) RefSNPs with at least two submitted SNPs, where at least one subquence, and RT-PCR was performed on RNA
mitted SNP is by noncomputational method and is not a cDNA; (3) SNPs validated by submitter
confirmation; or (4) SNPs validated by DoubleHit criteria.
pooled from multiple tissues. Three to 12
(NS) Nonsynonymous. PCR rescue and DNA synthesis clones have less than all or none of the
clones from each RT-PCR reaction were iso59- and 39-UTR sequences represented (see Methods).
lated. Following EST sequencing and gel
analysis, clones with the correct insert size
and 59- and 39-end sequences became candidates for full-insert
transcript targets uncharacterized in the literature were based on a
sequencing. After two RT-PCR cloning attempts, if one group failed
single high-throughput cDNA cloning report and lacked protein
to isolate a suitable cDNA clone for an assigned RefSeq transcript,
orthologs; in these cases, the annotated transcript was also ranked
that target was reassigned to the other group for another round of
based on the likelihood it contained a full-CDS. The full list of the
PCR rescue.
transcripts targeted by PCR rescue is provided in Supplemental
Clones containing CDS inserts shorter than the CDS of
Table A.
assigned transcripts were accepted into the MGC collection if
For DNA synthesis, only RefSeq accessions (Pruitt et al. 2009b)
they met the following criteria: (1) the protein alignment and
confirmed to be current and well supported by known transcripts
hexamer analysis (Strausberg et al. 2002) does not indicate that
and protein orthologs (accession prefix NM_) were assigned.
the CDS is partial; (2) the reading frame is consistent with
RefSeq transcripts containing predicted sequence (accession prefix
existing RefSeq records of the gene; and (3) the CDS length
XM_) were excluded. Candidates for DNA synthesis also unis equal to or greater than one-half of the longest RefSeq CDS of
derwent a final assessment by the NCBI RefSeq staff, to ensure that
the gene.
the CDS to be synthesized aligns to the genome and does not code

Table 3.

2.69
1.35
0.55

1.28
0.97
0.40

37.5%
46.6%
31.5%

Websites providing information on the Mammalian Gene Collection

URL

Description

http://mgc.nci.nih.gov/a
http://xgc.nci.nih.gov/
http://zgc.nci.nih.gov/
http://www.ncbi.nlm.nih.gov/genome/clone/
finding_cdna.shtml
http://www.ncbi.nlm.nih.gov/gene
http://www.ncbi.nlm.nih.gov/unigene
http://genome.ucsc.edu/
http://genome.ucsc.edu/goldenPath/help/
ucscGeneFishing.pdf

MGC website provides search engines, lists of genes and libraries, and information on
library construction, vectors, tissue sources, and resources for human, mouse, and rat. This
site includes ‘‘A Guide to Finding MGC Clones and Evaluating Their Sequence.’’
As above, but for Xenopus laevis and Xenopus tropicalis clones and information
As above, but for Danio rerio clones and information
‘‘Tips for Finding cDNA Clones’’ is an NCBI page with extensive details on locating
MGC clones.
Entrez Gene supports query by MGC clone designation and directs users to the cDNA
clone order page.
UniGene provides links to MGC/XGC/ZGC, supports retrieval of clusters with MGC
clones, and directs users to the cDNA clone order page.
UCSC Genome Browser provides tracks that can be activated to display MGC and
ORFeome Collaboration clones aligned with individual human genes. Links lead to
additional information on the clone, associated protein, and to ‘‘Order cDNA Clone.
This tutorial, ’’Fishing for Genes in the UCSC Browser,’’ includes a section on
accessing information on MGC clones.

a
The MGC web page allows users to search for available clones by keyword or gene symbol. Entering ‘‘p53’’ as a keyword or ‘‘TP53’’ as a gene symbol yields
the result that one MGC clone exists, named ‘‘BC003596’’; the library name and IMAGE ID are also given. Clicking on the library name shows that this
library was derived from a renal cell carcinoma and gives information on the library construction, vector, and bacterial host strain used. Following the link
to BC003596 provides full details on the clone nucleotide sequence and encoded protein sequence. This page provides an ‘‘Order cDNA Clone’’ link
(upper right corner) that lists the IMAGE distributors that offer this clone for sale, together with direct links to each distributor.
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DNA synthesis

DNA sequence submissions

Following a successful Pilot Study (Supplemental Text S2), MGC
assigned native protein-coding sequences (CDS) of RefSeq NMaccessions for synthesis to GeneArt (2564) and Codon Devices
(1177). A net total of 3647 targets (minus duplicates) were assigned. GeneArt synthesized the first ;90% of its assigned targets
in two versions, with a stop codon (TAA) and without a stop codon
(TAC). Subsequent assignments to both companies requested only
one version, with a stop codon (TAG). The largest CDS assigned
was 20,721 nt. Assigned sequences were designed with uniform
59- and 39-flanking sequences that include Gateway recombination
sites; and the full-CDS sequences plus flanking sequences were
cloned into a Gateway Entry vector, pENTR223.1, as described
(http://mgc.nci.nih.gov/Vectors). Final clones provided to MGC
were sequenced to MGC standards, as described below. The delivered CDS sequences were required to match exactly the assigned
RefSeq transcript.
In a small fraction of cases, the inserted sequence could not
be stably propagated in pENTR223.1, and those sequences were
provided to MGC in alternative vectors (indicated in the GenBank
record). MGC also required that its clones be delivered in phageresistant strains of Escherichia coli (tonA-, tonB-). Rarely, full-CDS
clones proved unstable in one or more phage-resistant E. coli
strains and were provided in non-phage-resistant strains. For 144
high-priority genes where the full-CDS insert proved unstable
in multiple vectors and host strains, MGC accepted stable
clones containing the CDS in multiple subfragments (listed in
Supplemental Table B). A list of all the assigned transcripts, with
their size and synthesis outcome, is included in Supplemental
Table A.

DNA sequencing was performed by standard capillary-based
methods, as described (Strausberg et al. 2002). All cDNA sequences
were submitted to GenBank together with phred quality scores, and
trace data were submitted to the NCBI Trace Archive. Clones
obtained from RT-PCR were required to meet the same stringent
sequencing quality that had been applied to clones from MGC
cDNA libraries (Strausberg et al. 2002; Gerhard et al. 2004): less
than one error per 50,000 bp, no uncertain base calls, and a phred
score of 30 or higher at each base pair. Synonymous and nonsynonymous changes were permitted within the protein-coding
sequences of PCR rescue clones, but changes that altered the phase
of CDS reading frame or introduced premature stop codons were
not permitted. Clones with 59 UTRs longer than 500 nt were
manually curated. Clones with a stop codon more than 55 nt 59 to
a splice junction and with a CDS at least 50% of the longest isoform
CDS were accepted into MGC, but were annotated in the GenBank
record as likely NMD candidates. All sequence differences between
the cDNA sequences and their genome are annotated in the
GenBank entry (misc_feature).

Single-exon gene (SEG) predictions
Computational methods were used to screen the NCBI human
genome sequence (Build 36.1) for all open reading frames (ORFs) of
length at least 200 bp and to select the 351 most promising SEG
candidates. To distinguish likely SEGs from pseudogenes, we used
syntenic alignments between the human and other mammalian
genomes; conservation of ORFs in multiple alignments with
mouse, rat, and dog; homology with known proteins and domain
profiles; whole-genome gene expression data; and other properties
of each ORF. These features were integrated by logistic regression,
after training the algorithms with both positive examples (known
SEGs) and negative (known and predicted pseudogenes).
Expression was confirmed for 198 out of 351 selected candidates by RT-PCR, with RT-controls to detect results due to genomic
contamination. Many of the weakest candidates appear to be
fragments of pseudogenes. Indeed, we obtained an even higher
percentage of expressed ORFs (67% vs. 56%) among a negative
reference set of loci selected from annotated pseudogenes and regions annotated as intronic or intergenic by the ENCODE pilot
project. Positive results for predicted SEGs and negative reference
loci were confirmed by DNA sequence analysis of ‘‘mini-pools’’ of
cloned RT-PCR products. A list of the SEG candidate and negative
reference loci is provided in Supplemental Table S1. To find possible matches against human proteins, Vineet Bafna’s group
(University of California, San Diego) screened our set of predicted
SEGs against an existing database of MS/MS spectra from human
kidney cell lines (http://bioinfo2.ucsd.edu/MSGeneAnnotation/
index.html; Tanner et al. 2007), verifying protein products of nine
of the 198 putative expressed SEGs (V Bafna, pers. comm.).

RNA editing analysis
Two tests were used to identify clones with putative A-to-G edits.
For test 1, we followed Kim et al. (2004) to identify clones with at
least one window of 100 nt that has: (1) more than five A-to-G
changes and (2) more than half of the total number of differences
with the genomic DNA as A-to-G changes. The 113 clones that
meet these criteria are given in Supplemental Table S4. Putative
edits reported as validated single-nucleotide polymorphisms
(multiple observed polymorphisms or genotyped polymorphisms
with minor allele frequency exceeding 2%) were discarded. No
clones with equivalent windows of G-to-A changes were identified,
although two clones with equivalent T-to-C changes and three
clones with C-to-T changes were identified, suggesting a falsepositive rate of ;2% in this list of A-to-G candidate edits.
Our second test identified clones that harbor at least one 100nt window of sequence with enough changes of a single type that
the probability of observing this window by chance is 10 8. We
defined the probability of observing a window with m changes as
P = 0.25Nrm where r is the observed mismatch rate per clone and N
is the number of genomic instances of the original nucleotide in
the sequence window (number of As for A-to-I editing). (Since
transitions are more common than transversions, 0.25 is a slight
underestimate of the number of changes expected for any single
type of transition.) We set P to 10 8, which means that for each
100-nt window, we assessed whether there are m changes where
m = log(10 8/0.25N)/log(r). We identified 118 clones with at least
one such window of m A-to-G changes and two clones with G-to-A
changes (Supplemental Table S5). These 118 clones include 87
clones identified by test 1 (Supplemental Table S6). Additional
methods and results are described in Supplemental Text S3.
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